IRIS
RUSSO, Simonetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 910
NA - Nord America 754
AS - Asia 337
SA - Sud America 1
Totale 2.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 751
CN - Cina 268
IT - Italia 219
FI - Finlandia 214
IE - Irlanda 187
SE - Svezia 151
DE - Germania 70
TR - Turchia 58
FR - Francia 30
UA - Ucraina 12
BE - Belgio 11
GB - Regno Unito 7
CZ - Repubblica Ceca 5
IN - India 5
CA - Canada 3
HU - Ungheria 3
SG - Singapore 3
VN - Vietnam 2
BR - Brasile 1
PK - Pakistan 1
RU - Federazione Russa 1
Totale 2.002
Salva come PNG Salva come JPEG
Città #
Chandler 191
Dublin 187
Ann Arbor 114
Parma 111
Beijing 63
Dearborn 51
Izmir 47
Nanjing 39
Ashburn 36
Jacksonville 30
Princeton 28
Bremen 27
Shanghai 25
Wilmington 24
New York 14
Kunming 13
Shenyang 13
Helsinki 12
Hebei 11
Hefei 11
Nanchang 11
Brussels 10
Düsseldorf 10
Los Angeles 10
San Mateo 10
Boardman 8
Grafing 8
Hangzhou 8
Jinan 8
Kocaeli 8
Guangzhou 7
Fremont 6
Jiaxing 6
Modena 6
Seattle 6
Changsha 5
Milan 5
Prata Di Pordenone 5
Woodbridge 5
Zhengzhou 5
Des Moines 4
Fuzhou 4
Palermo 4
Sant'ilario D'enza 4
Ankara 3
Brno 3
Fairfield 3
Haikou 3
Norwalk 3
Pune 3
Tianjin 3
Toronto 3
Torrance 3
Vigevano 3
Brescia 2
Caorso 2
Carpi 2
Dong Ket 2
Highland Park 2
Houston 2
Lissone 2
Montegaldella 2
Munich 2
Ningbo 2
Rimini 2
Soliera 2
Taizhou 2
Trezzano Sul Naviglio 2
Xian 2
Amherst 1
Auburn Hills 1
Bologna 1
Borås 1
Cremona 1
Frontone 1
Leuven 1
Messina 1
Nashville 1
New Delhi 1
Noceto 1
Orange 1
Parabita 1
Paris 1
Pavia 1
Poggio Renatico 1
Redmond 1
Reggio Nell'emilia 1
Rho 1
San Giuliano Milanese 1
Segrate 1
Shaoxing 1
Simi Valley 1
Taiyuan 1
Tappahannock 1
Tulsa 1
Viterbo 1
Washington 1
Totale 1.298
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 142
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 131
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 114
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 110
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 99
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 96
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 90
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 83
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 75
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 74
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 72
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 71
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 70
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 69
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 67
Structure activity relationship of new EphA2 ligands 64
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 64
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 64
Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey 64
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 63
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 62
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 57
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 51
Mannich base derivatives as novel EGFR irreversible inhibitors 49
Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism 48
Target-hopping: a useful approach to identify novel Eph receptor antagonists 47
Structure-activity realtionships of new EphaA2 ligands 40
Mechanical vibrations applied to nondestructive evaluation of materials and structures 30
Totale 2.066
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201952 0 0 0 0 0 0 0 0 0 0 52 0
2019/2020367 64 60 13 11 19 48 47 10 41 37 8 9
2020/2021201 9 8 14 15 14 18 19 8 36 25 17 18
2021/2022179 9 10 9 38 4 11 14 11 5 12 8 48
2022/2023668 75 84 25 53 70 75 12 36 219 4 13 2
2023/2024162 16 16 5 9 8 35 32 21 10 10 0 0
Totale 2.066